Daiichi Sankyo sends US QA director to rescue Ranbaxy India ops; FDA urged to mandate closer vaccine scrutiny;

> Japan's Daiichi Sankyo has named U.S. QA director Dale Adkisson to oversee the quality and manufacturing efforts at Ranbaxy Labs in India, one of the FDA's GMP violation poster children. Article

> Following the rotavirus contamination, the FDA is being urged to require checks for barely detectable biological matter in vaccine-making. Article

> Anika Therapeutics says the FDA has OK'd corrective actions following a 2008 GMP warning letter. Article

> Boehringer Ingelheim has chosen Kuehne + Nagel to management temperature-controlled transportation in the Czech Republic, Poland, Hungary, Greece and Croatia. Release

> Simcere Pharmaceutical's Jiangsu Yanshen Biological has been fined $3.74 million by the Changzhou Food and Drug Administration for production of substandard human rabies vaccine, plus $3.36 million to cover the cost of patient re-vaccinations. Release

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.